Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 63

1.

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study.

Zuckerman T, Ram R, Akria L, Koren-Michowitz M, Hoffman R, Henig I, Lavi N, Ofran Y, Horowitz NA, Nudelman O, Tavor S, Yeganeh S, Gengrinovitch S, Flaishon L, Tessler S, Ben Yakar R, Rowe JM.

Blood Adv. 2019 Nov 26;3(22):3740-3749. doi: 10.1182/bloodadvances.2019000468.

2.

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases.

Sant'Antonio E, Guglielmelli P, Pieri L, Primignani M, Randi ML, Santarossa C, Rumi E, Cervantes F, Delaini F, Carobbio A, Betti S, Rossi E, Lavi N, Harrison CN, Curto-Garcia N, Gisslinger H, Gisslinger B, Specchia G, Ricco A, Vianelli N, Polverelli N, Koren-Michowitz M, Ruggeri M, Girodon F, Ellis M, Iurlo A, Mannelli F, Mannelli L, Sordi B, Loscocco GG, Cazzola M, De Stefano V, Barbui T, Tefferi A, Vannucchi AM.

Am J Hematol. 2019 Nov 12. doi: 10.1002/ajh.25677. [Epub ahead of print]

PMID:
31721282
3.

Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study.

Ofran Y, Hayun M, Leiba R, Zuckerman T, Horowitz N, Hoffman R, Ringelstein S, Lavi N, Frisch A, Henig I, Gatt ME, Hellmann I, Arad A, Bulvik S, Ram R, Gino-Moor S, Saban R, Tvito A, Rowe JM, Ganzel C.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25651. [Epub ahead of print] No abstract available.

PMID:
31591736
4.

Newly diagnosed myeloma patients with low-burden disease may benefit from tandem autologous stem cell transplantation: results of long-term follow-up.

Benyamini N, Lavi N, Zuckerman T, Aviv A, Rowe JM, Katz T.

Bone Marrow Transplant. 2019 Sep 16. doi: 10.1038/s41409-019-0671-5. [Epub ahead of print] No abstract available.

PMID:
31527816
5.

Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy.

Beyar-Katz O, Magidey K, Reiner-Benaim A, Barak N, Avivi I, Cohen Y, Timaner M, Avraham S, Hayun M, Lavi N, Bersudsky M, Voronov E, Apte RN, Shaked Y.

Mol Cancer Res. 2019 Nov;17(11):2331-2340. doi: 10.1158/1541-7786.MCR-19-0487. Epub 2019 Aug 13.

PMID:
31409628
6.

Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.

Perry C, Ben Barouch S, Goldschmidt N, Sarid N, Herishanu Y, Shvidel L, Bairey O, Lavi N, Horowitz N, Avigdor A, Lebel E, Sofer O, Ram R, Avivi I.

Am J Hematol. 2019 Jun 18. doi: 10.1002/ajh.25558. [Epub ahead of print]

PMID:
31211434
7.

Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.

Beyar-Katz O, Lavi N, Ringelstein-Harlev S, Henig I, Yehudai-Ofir D, Haddad N, Fineman R, Ofran Y, Nov Y, Sahar D, Moustafa-Hawash N, Rowe JM, Zuckerman T.

Leuk Lymphoma. 2019 Oct;60(10):2449-2456. doi: 10.1080/10428194.2019.1594214. Epub 2019 Apr 3.

PMID:
30943060
8.

Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms.

Barzilai M, Kirgner I, Avivi I, Ellis M, Dally N, Rozovski U, Lavi N.

Eur J Haematol. 2019 Jun;102(6):504-508. doi: 10.1111/ejh.13232. Epub 2019 Apr 25.

PMID:
30941804
9.

Baseline Chest Computed Tomography for Early Diagnosis of Invasive Pulmonary Aspergillosis in Hemato-oncological Patients: A Prospective Cohort Study.

Bitterman R, Hardak E, Raines M, Stern A, Zuckerman T, Ofran Y, Lavi N, Guralnik L, Frisch A, Nudelman O, Paul M, Oren I.

Clin Infect Dis. 2019 Oct 30;69(10):1805-1808. doi: 10.1093/cid/ciz194.

PMID:
30855077
10.

Severe cytomegalovirus enterocolitis developing following daratumumab exposure in three patients with multiple myeloma.

Lavi N, Okasha D, Sabo E, Oren I, Benyamini N, Bar-Yoseph H.

Eur J Haematol. 2018 Aug 18. doi: 10.1111/ejh.13164. [Epub ahead of print]

PMID:
30120798
11.

Semaphorin-3A inhibits multiple myeloma progression in a mouse model.

Lavi N, Kessler O, Ziv K, Nir-Zvi I, Mumblat Y, Eiza N, Paran Y, Brenner B, Vadasz Z, Neufeld G.

Carcinogenesis. 2018 Oct 8;39(10):1283-1291. doi: 10.1093/carcin/bgy106.

PMID:
30102336
12.

Decreased amplitude of surface electromyo- graphic recordings of muscle activation along the posterior myofascial kinematic chain in subjects with chronic nonspecific low back pain compared to healthy subjects.

Vulfsons S, Chervonenko S, Haddad M, Weisman MH, Lavi N, Dar G.

J Back Musculoskelet Rehabil. 2018;31(4):785-793. doi: 10.3233/BMR-160627.

PMID:
29865025
13.

Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study.

Cohen YC, Saranga A, Gatt ME, Lavi N, Ganzel C, Magen H, Avivi I, Tadmor T, Suriu C, Jarchowsky Dolberg O, Papushado A, Trestman S, Ram R.

Am J Hematol. 2018 Jun;93(6):810-815. doi: 10.1002/ajh.25098. Epub 2018 Apr 28.

14.

Community-acquired respiratory infections are common in patients with non-Hodgkin lymphoma and multiple myeloma.

Lavi N, Avivi I, Kra-Oz Z, Oren I, Hardak E.

Support Care Cancer. 2018 Jul;26(7):2425-2431. doi: 10.1007/s00520-018-4079-3. Epub 2018 Feb 9.

PMID:
29427192
15.

How Do Hunter-Gatherer Children Learn Subsistence Skills? : A Meta-Ethnographic Review.

Lew-Levy S, Reckin R, Lavi N, Cristóbal-Azkarate J, Ellis-Davies K.

Hum Nat. 2017 Dec;28(4):367-394. doi: 10.1007/s12110-017-9302-2. Review.

16.

Ruxolitinib for the management of myelofibrosis: Results of an international physician survey.

Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN.

Leuk Res. 2017 Oct;61:6-9. doi: 10.1016/j.leukres.2017.08.002. Epub 2017 Aug 10.

PMID:
28843161
17.

Allogeneic stem-cell transplantation for myelofibrosis.

Lavi N, Rowe JM, Zuckerman T.

Curr Opin Hematol. 2017 Nov;24(6):475-480. doi: 10.1097/MOH.0000000000000381. Review.

PMID:
28832353
18.

Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell Lymphoma.

Lavi N, Shapira G, Zilberlicht A, Benyamini N, Farbstein D, Dann EJ, Bar-Shalom R, Avivi I.

Isr Med Assoc J. 2016 Jul;18(7):411-417.

19.

Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.

Benyamini N, Avivi I, Dann EJ, Zuckerman T, Lavi N, Katz T.

Ann Hematol. 2017 Mar;96(3):461-467. doi: 10.1007/s00277-016-2897-2. Epub 2016 Dec 24.

PMID:
28013359
20.

Site Formation Processes and Hunter-Gatherers Use of Space in a Tropical Environment: A Geo-Ethnoarchaeological Approach from South India.

Friesem DE, Lavi N, Madella M, Ajithprasad P, French C.

PLoS One. 2016 Oct 26;11(10):e0164185. doi: 10.1371/journal.pone.0164185. eCollection 2016.

Supplemental Content

Support Center